Biocardia Inc (BCDA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.15 (+3.60%), Market cap $0.01B, 52-week low–high $0.90 ~ $2.42.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In a
Financial statements, price targets, institutional (13F) holdings and related news for Biocardia Inc are updated in real time on BlackAll Trade.
Biocardia Inc trades at $1.15 (+3.60%). Real-time quotes and charts are available on BlackAll Trade.
Biocardia Inc has a market cap of about $0.01B.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead prod